Achilles Therapeutics

London, United Kingdom Founded: 2016 • Age: 10 yrs
T-cell therapies targeting tumor neo-antigens for cancer are developed.
Request Access

About Achilles Therapeutics

Achilles Therapeutics is a company based in London (United Kingdom) founded in 2016 by Charles Swanton, Sergio Quezada, Mark Lowdell, and Karl Peggs.. Achilles Therapeutics has raised $241.98 million across 5 funding rounds from investors including Syncona, Orbimed and RA Capital. The company has 118 employees as of December 31, 2020. Achilles Therapeutics operates in a competitive market with competitors including Celgene, Caribou Biosciences, Poseida Therapeutics, Juno Therapeutics and Senti Biosciences, among others.

  • Headquarter London, United Kingdom
  • Employees 118 as on 31 Dec, 2020
  • Founders Charles Swanton, Sergio Quezada, Mark Lowdell, Karl Peggs
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Achilles Therapeutics Plc
  • Date of Incorporation 18 Nov, 2020
  • Jurisdiction LONDON, UNITED KINGDOM
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
    $-54.68 M (USD)
    -64
    as on Dec 31, 2019
  • EBITDA
    $-64.63 M (USD)
    -65
    as on Dec 31, 2019
  • Total Equity Funding
    $241.98 M (USD)

    in 5 rounds

  • Latest Funding Round
    $4.08 M (USD), Grant

    Jul 21, 2022

  • Investors
    Syncona

    & 10 more

  • Employee Count
    118

    as on Dec 31, 2020

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Achilles Therapeutics
Headcount 10-50
Employee Profiles 26
Board Members and Advisors 5
Employee Profiles
People
Robert Coutts
CFO
People
Pablo D. Becker
Head Of Immunology Research
People
Samuel Jide-Banwo
Senior Scientist
People
Tariq Ahmed
EVP People

Unlock access to complete

Board Members and Advisors
people
Mark Lowdell
Scientific Advisor
people
Edwin Moses
Chairman, Board of Directors
people
Charlie Swanton
Scientific Advisor
people
Carsten Boess
Non-Executive Director

Unlock access to complete

Funding Insights of Achilles Therapeutics

Achilles Therapeutics has successfully raised a total of $241.98M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $4.08 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Grant — $4.1M
  • First Round

    (24 May 2016)

  • Investors Count 11
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2022 Amount Grant - Achilles Therapeutics Valuation

investors

Jun, 2021 Amount Grant - Achilles Therapeutics Valuation

investors

Nov, 2020 Amount Series C - Achilles Therapeutics Valuation Orbimed , Boxer Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Achilles Therapeutics

Achilles Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Syncona, Orbimed and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
Founded Year Domain Location
Biotech startups are funded by this venture capital firm.
Founded Year Domain Location
Healthcare investments are managed via private equity by Syncona.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Achilles Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Achilles Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Achilles Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Achilles Therapeutics

Achilles Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, Caribou Biosciences, Poseida Therapeutics, Juno Therapeutics and Senti Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapies for cancer and inflammatory diseases are developed.
domain founded_year HQ Location
Provider of cell therapies to treat cancer and hematologic conditions
domain founded_year HQ Location
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
domain founded_year HQ Location
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
domain founded_year HQ Location
Cell-based therapies for cancer treatment are developed.
domain founded_year HQ Location
T cell-based treatments for immunological and oncological disorders are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Achilles Therapeutics

Frequently Asked Questions about Achilles Therapeutics

When was Achilles Therapeutics founded?

Achilles Therapeutics was founded in 2016.

Where is Achilles Therapeutics located?

Achilles Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Is Achilles Therapeutics a funded company?

Achilles Therapeutics is a funded company, having raised a total of $241.98M across 5 funding rounds to date. The company's 1st funding round was a Series C of $97.5M, raised on May 24, 2016.

How many employees does Achilles Therapeutics have?

As of Dec 31, 2020, the latest employee count at Achilles Therapeutics is 118.

What does Achilles Therapeutics do?

Achilles Therapeutics was established in 2016 in London, United Kingdom, within the biotechnology sector focused on oncology. T-cell therapies are developed to target neo-antigens, unique surface markers on cancer cells that signal the immune system. Emphasis is placed on treatments for lung cancer, recurrent metastatic melanoma, and head and neck squamous cell carcinomas. Operations involve research and therapeutic development in this specialized field.

Who are the top competitors of Achilles Therapeutics?

Achilles Therapeutics's top competitors include Immunocore, Juno Therapeutics and Senti Biosciences.

Who are Achilles Therapeutics's investors?

Achilles Therapeutics has 11 investors. Key investors include Syncona, Orbimed, RA Capital, Cancer Research UK, and European Union.

What is Achilles Therapeutics's valuation?

The valuation of Achilles Therapeutics is $165.6M as of Sep 2019.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available